GARDASIL(R) Demonstrated Efficacy In Preventing HPV-Related Disease In Males In Phase III Study
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.
More: continued here
Filed under: Cervical Cancer on November 21st, 2008